IP Library › Patent Application 18188721
Patent Application
App. No. 18/188,721

COMBINATION THERAPY FOR TREATING CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/188,721
Abstract

The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.

Claims (33)

1 . A method for treating a malignant rhabdoid tumor (MRT) or an atypical teratoid/rhabdoid tumor (AT/RT) comprising administering to a subject:

(a)

 (tazemetostat), or a pharmaceutically acceptable salt thereof, and

(b) vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib.

2 - 8 . (canceled)

9 . The method of claim 1 , wherein the vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib is administered prior to the tazemetostat.

10 . The method of claim 1 , wherein the tazemetostat is administered prior to the vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib.

11 - 13 . (canceled)

14 . A method for treating a malignant rhabdoid tumor (MRT) or an atypical teratoid/rhabdoid tumor (AT/RT), the method comprising sensitizing a subject, wherein sensitizing comprises administering to the subject:

(tazemetostat), or a pharmaceutically acceptable salt thereof, and

(b) vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib.

15 - 30 . (canceled)

31 . A method of inhibiting or decreasing growth, viability, survival, or proliferation of a cancer cell comprising (1) contacting the cell with (a) an effective amount of EZH2 inhibitor, and (b) one or more second agents, or (2) contacting the cell with an effective amount of EZH2 inhibitor and exposing the cell to a radiation, wherein the cancer cell is an atypical teratoid rhabdoid tumor cell or a malignant rhabdoid tumor cell.

32 - 39 . (canceled)

40 . The method of claim 1 , wherein the tazemetostat is administered orally.

41 . (canceled)

42 . The method of claim 1 , wherein the subject is a human being.

43 . (canceled)

44 . The method of claim 1 , wherein the tazemetostat is administered to the subject at a dose of about 100 mg to about 3200 mg daily.

45 - 46 . (canceled)

47 . The method of claim 44 , wherein the tazemetostat is administered to the subject at a dose of 800 mg BID.

48 .- 91 . (canceled)

92 . The method of claim 1 , comprising administering entinostat or romidepsin to the subject.

93 . The method of claim 92 , comprising administering entinostat to the subject.

94 . The method of claim 92 , comprising administering romidepsin to the subject.

95 . The method of claim 1 , wherein the method is for treating an MRT.

96 . The method of claim 1 , wherein the method is for treating an AT/RT.

97 . The method of claim 92 , wherein the method is for treating an MRT.

98 . The method of claim 92 , wherein the method is for treating an AT/RT

99 . The method of claim 1 , comprising administering vincristine to the subject.

100 . The method of claim 1 , comprising administering topotecan to the subject.

101 . The method of claim 1 , comprising administering palbociclib to the subject.

102 . The method of claim 1 , comprising administering trametinib to the subject.